scholarly journals Money Talks

2017 ◽  
Vol 11 (5) ◽  
pp. 373-374 ◽  
Author(s):  
George E. Guthrie

The cost of providing medical care is increasing. The driving forces include inherent health care system conflicts of interest and financial incentives for procedures and technology. Effective lifestyle medicine principles are not easily adopted and rewarded in the present environment. Recent moves toward outcomes-based pay systems offer the potential to demonstrate the effectiveness of lifestyle medicine principles while bypassing many of the biases, application delays, and political machinations of the traditional randomized control trial methodology. The American College of Lifestyle Medicine is uniquely positioned to be a leading organization in improving health, enhancing patient experience, and reducing the cost of care.

2019 ◽  
Vol 25 (1) ◽  
pp. 126-139
Author(s):  
Joanna E Cannon ◽  
Anita M Hubley ◽  
Julia I O’Loughlin ◽  
Lauren Phelan ◽  
Nancy Norman ◽  
...  

Abstract The purpose of this study was to examine the effectiveness of a technology-based intervention (LanguageLinks: Syntax Assessment and Intervention®; Laureate Learning Systems, Inc., 2013) to improve reading comprehension for d/Deaf and hard of hearing (DHH) elementary students. The intervention was a self-paced, interactive program designed to scaffold learning of morphosyntax structures. Participants included 37 DHH students with moderate to profound hearing levels, 7–12 years of age, in Grades 2–6. Assessment data were collected pre- and post- an 8-week intervention using a randomized control trial methodology. Findings indicate the intervention did not appear to be effective in improving performance, and 17 out of 36 morphosyntax structures were found difficult to comprehend for participants in the treatment group. These difficult structures included aspects of pronominalization, the verbal system, and number in nouns. Results are compared to previous research, with recommendations for future areas of research related to increasing knowledge of morphosyntax for learners who are DHH.


2021 ◽  
Vol 15 (10) ◽  
pp. 2652-2655
Author(s):  
Mehreen Akram ◽  
Iqra Mushtaq ◽  
Rafia Kousar

Background: OCR commonly occurs during strabismus surgery, producing bradycardia, arrhythmias and even cardiac arrest after manipulation of orbital structures. Ketamine is NMDA receptor antagonist and acts as an analgesic. Aim: To determine the effect of ketamine premedication on prevention of OCR during strabismus surgery. Study design: Randomized control trial Methodology: 60 patients were randomly divided into two groups i.e., Ketamine 0.75mg/kg (Group K) and control (Group C). Group K patients were premedicated with 0.75mg/kg ketamine while Group C patients did not receive any premedication. Heart rate and ECG were observed 30 sec before and continuously after traction on extraocular muscles was applied upto end of surgery for bradycardia and arrhythmias. Percentage change in HR and presence of arrhythmias was documented. All the data was collected using case report form and analyzed using SPSS version 15. Results: In Group C, 15(50%) cases had arrhythmias while in Group K, only 4(13.33%) cases had arrhythmias. Mean HR in Group C was 118.77±6.92/min and in Group K was 101.57±15.65/min. In Group C, oculocardiac reflex was present in 23(76.7%) cases and in Group K, OCR was present in 6 (20%) cases and prevented in 24 (80%) cases. Conclusion: Premedication with 0.75mg/kg IV ketamine significantly reduces the occurrence of oculocardiac reflex during strabismus surgery. Keywords: Ketamine, Oculocardiac Reflex, Premedication, Prevention, Strabismus


2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Takroni MA ◽  
Albarrati A ◽  
Akomolafe T ◽  
Al Enazy M

Introduction: Early Mobilization (EM) of patients in Intensive Care Unit (ICU) has received considerable attention in scientific literature over the past several years. It has been reported that EM decrease Hospital Length of Stay (LOS).


2019 ◽  
Vol 28 (11) ◽  
pp. 1902-1908 ◽  
Author(s):  
Alicea Lieberman ◽  
Ayelet Gneezy ◽  
Emily Berry ◽  
Stacie Miller ◽  
Mark Koch ◽  
...  

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5914-5914
Author(s):  
Li Zhou ◽  
Bingcheng Liu ◽  
Jianda Hu ◽  
Jianhua Qu ◽  
Ming Hou ◽  
...  

Background: Imatinib is the first TKI that was officially approved by the Food and Drug Administration (FDA) for the treatment of patients (pts) with CP-CML and it is the most commonly used treatment in CML pts on the international scene. Generic imatinib was offered and accessible as frontline treatment of CML in china in June 2013, which predictably lowered the cost of CML therapy. However the statistics regarding their effectiveness and tolerability in greater proportion of the population of CML pts are not available. (ClinicalTrials. gov number, NCT02317159.) Aim: To evaluate the efficacy and safety of generic imatinib in the treatment of pts that were newly diagnosed with CP-CML. Methods: In this multi-center, prospective open-label study, 75 pts with CP-CML were enrolled to receive generic imatinib mesylate capsules at a dose of 400 mg once daily. The primary end point was major molecular response (MMR) by 12 months. Imatinib plasma level and adverse events (AEs) were assessed. Results: The Median age at diagnosis was 46 years (range 19-75 years), and 50 pts (66.7%) were male. The median follow-up was 22.1 (range0.5-24) months. 35 pts (44%), 26 pts (34.7%) and 12 pts (16%) were in low, intermediate and high risk group, respectively, according to Sokal prognostic score (Not available in 2 pts). By 12 months, the cumulative rate of MMR (BCR-ABL1IS ≤0.1%) was 42.7% (32/75), and the cumulative rate of complete cytogenic response (CCyR) was74.7% (56/75). Complete hematologic response (CHR), CCyR, MMR rate at 3 months,6 months and 12 months were shown in Table 1. For pts who presented with BCR-ABL1 IS≤ 10% at 3 months, had better response as compared with those with BCR/ABL1IS> 10% (Table 2). The estimated progression-free survival at 12 months was 94.7%. Imatinib plasma levels at 29 days on imatinib were variable in individual, with 1522.9±775.3 ng/mL for median level (rang 394.4 to3891 ng/mL). Although those numerical values showed difference, no statistically significant correlations were found between imatinib plasma level and CCyR or MMR(P=0.902;P=0.349). The incidents and profile of AEs were similar to those reported previously. Conclusion: This study confirmed that generic imatinib produced in China is effective and well-tolerated in Chinese CP-CML pts. The outcome of generic imatinib in the treatment of CP-CML is similar to brand imatinib reported in the literatures. The introduction of generic imatinib at a reduced and affordable cost may strikingly impact the cost of care for CML and improve the clinical outcomes of CML in China. Disclosures No relevant conflicts of interest to declare.


Author(s):  
Ankasha Arif ◽  
Eatzaz Ahmad ◽  
Farzana Naheed Khan

This study analyzes the impact of education, health policy initiatives i.e. selection of treatment arms of ambulatory vs. hospital care and financial incentives under taken by the National Tuberculosis Program of Pakistan (NTP) on the outcome of cure of multi-drug resistance tuberculosis patients. The data of 370 patients enrolled in randomized control trial is collected from three TB centers of Lahore, Karachi and Murree and multi-variate logistic regression method is applied. The empirical findings show that formal education and selection of treatment arm do not significantly affect the outcome of the cure. However, health literacy provided by the NTP plays vital role in improving the treatment outcomes. Therefore, it is suggested that health literacy should be focused in our formal education for the improvement of the health-status of the nation. Moreover, WHO (2011) recommendation of shift towards ambulatory care is applicable for Pakistan and financial incentives should continue as it reduces the treatment burden for patients.


2020 ◽  
Author(s):  
Bryan Yijia Tan ◽  
Michelle Jessica PEREIRA ◽  
Yang Su-Yin ◽  
David J. Hunter ◽  
Soren Thorgaard SKOU ◽  
...  

Abstract Background: Knee Osteoarthritis (OA) is a leading cause of global disability, with most patients not receiving optimal non-surgical treatment resulting in significant morbidity and cost to the healthcare system, The Collaborative Model of Care between Orthopaedics and Allied Healthcare Professionals (CONNACT) Model of Care (MoC) was developed by optimizing evidence-based non-surgical treatments to deliver value-based care for people with knee OA. The primary aim of this study is to determine the clinical effectiveness of the CONNACT MoC compared to usual care. The secondary aims are: a) To determine the cost-effectiveness and b) To develop an evaluation and implementation framework to inform large scale implementation for this MoC. Design: A Type 1 Effectiveness-Implementation Hybrid Trial using an explanatory sequential mixed-method approach. Methodology: The study consists of 3 components. The first component is the pragmatic, parallel-arm, single-blinded randomized control trial. Inclusion criteria are patients with knee OA based on the National Institute of Health and Care Excellence (NICE) criteria with radiographic severity of greater than Kellgren-Lawrence 1, and Knee Injury and OA Outcome Score (KOOS4) of equal or less than 75. Exclusion criteria include other forms of arthritis, history of previous knee arthroplasty or wheelchair-bound patient. The intervention arm will undergo the CONNACT MoC while the usual care arm will be referred to the physiotherapist where the number and content of sessions are at the patient’s and physiotherapist’s discretion. The CONNACT MoC is a community-based, multidisciplinary 12-week program that uniquely uses an individualized approach based on a triaging criterion to tailor the treatment to each patient in line with the “right care, delivered at the right time, by the right team, in the right place, with the right resources” philosophy coupled with a strong emphasis on patient activation and self-management strategies to promote long term sustainable behavioural change. KOOS4 is the primary outcome measure. Secondary outcomes include KOOS individual subscales, quality of life scoring, functional performance, global, diet and psychological related outcomes. The second component is an economic evaluation of the cost-effectiveness of the CONNACT MoC using a societal perspective. The third component is an implementation and evaluation framework using process evaluation under the RE-AIM framework using a mixed-method approach. Discussion: A rapidly aging global population has resulted in an OA epidemic that is currently being poorly managed on a global scale. CONNACT MoC is a complex intervention that has been developed to meet this growing need. In line with the MRC guidance for developing and evaluating complex interventions, a pilot feasibility study was completed and a comprehensive approach including an RCT, economic evaluation and process evaluation is described in this study protocol. Results from this study will help clinicians, healthcare administrators and policymakers guide the sustainable and effective implementation of the CONNACT MoC for knee OA and serve as a basis for similar multidisciplinary MoC for chronic degenerative musculoskeletal conditions to be developed.Trial Registration: Clinicaltrials.gov Identifier: NCT03809975. Registered January 18 2019. https://clinicaltrials.gov/ct2/show/NCT03809975


2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Bryan Yijia Tan ◽  
Michelle Jessica Pereira ◽  
Su-Yin Yang ◽  
David J. Hunter ◽  
Soren Thorgaard Skou ◽  
...  

Abstract Background Knee Osteoarthritis (OA) is a leading cause of global disability. The Collaborative Model of Care between Orthopaedics and Allied Healthcare Professionals (CONNACT) Model of Care (MoC) was developed by optimizing evidence-based non-surgical treatments to deliver value-based care for people with knee OA. The primary aim of this study is to determine the clinical effectiveness of the CONNACT MoC (3 months) compared to usual care. The secondary aims are: a) To determine the cost-effectiveness and b) To develop an evaluation and implementation framework to inform large scale implementation for this MoC. Methodology Type 1 Effectiveness-Implementation Hybrid Trial using an explanatory sequential mixed-method approach. The study consists of 3 components. The first component is the pragmatic, parallel-arm, single-blinded randomized control trial. Inclusion criteria are patients with knee OA based on the National Institute of Health and Care Excellence (NICE) criteria with radiographic severity of greater than Kellgren-Lawrence 1, and Knee Injury and OA Outcome Score (KOOS4) of equal or less than 75. Exclusion criteria include other forms of arthritis, history of previous knee arthroplasty or wheelchair-bound patient. KOOS4 is the primary outcome measure at 3 months, 6 months and 1 year. Secondary outcomes include KOOS individual subscales, quality of life scoring, functional performance, global, diet and psychological related outcomes. The second component is an economic evaluation of the cost-effectiveness of the CONNACT MoC using a societal perspective. The third component is an implementation and evaluation framework using process evaluation under the RE-AIM framework using a mixed-method approach. Sample size of 100 patients has been calculated. Discussion CONNACT MoC is a complex intervention. In line with the MRC guidance for developing and evaluating complex interventions, a pilot feasibility study was completed and a comprehensive approach including an RCT, economic evaluation and process evaluation is described in this study protocol. Results from this study will help clinicians, healthcare administrators and policymakers guide the sustainable and effective implementation of the CONNACT MoC for knee OA and serve as a basis for similar multidisciplinary MoC for chronic degenerative musculoskeletal conditions to be developed. Trial registration Clinicaltrials.gov Identifier: NCT03809975. Registered January 182,019.


2005 ◽  
Author(s):  
Suzanne Tough ◽  
D. Johnston ◽  
J. Siever ◽  
G. Jorgenson ◽  
L. Slocombe ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document